Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 26

1.

Characterizing Good Review Practices: A Survey Report Among Agencies of APEC Member Economies.

Liu LL, McAuslane N, Tzou MC, Chern HD, Liberti L, Ward M, Kang JJ.

Ther Innov Regul Sci. 2013 Nov;47(6):678-683. doi: 10.1177/2168479013494394.

PMID:
30235555
2.

Role of omeprazole dosage and cytochrome P450 2C19 genotype in patients receiving omeprazole-amoxicillin dual therapy for Helicobacter pylori eradication.

Yang JC, Wang HL, Chern HD, Shun CT, Lin BR, Lin CJ, Wang TH.

Pharmacotherapy. 2011 Mar;31(3):227-38. doi: 10.1592/phco.31.3.227.

PMID:
21361732
3.

Proposals of statistical consideration to evaluation of results for a specific region in multi-regional trials--Asian perspective.

Tsou HH, Chow SC, Lan KK, Liu JP, Wang M, Chern HD, Ho LT, Hsiung CA, Hsiao CF.

Pharm Stat. 2010 Jul-Sep;9(3):201-6. doi: 10.1002/pst.442.

PMID:
20568264
4.

CYP2C9 polymorphism and warfarin sensitivity in Taiwan Chinese.

Chern HD, Ueng TH, Fu YP, Cheng CW.

Clin Chim Acta. 2006 May;367(1-2):108-13. Epub 2006 Jan 17.

PMID:
16413010
5.

Time-dependent amplified pharmacokinetic and pharmacodynamic responses of rabeprazole in cytochrome P450 2C19 poor metabolizers.

Lin CJ, Yang JC, Uang YS, Chern HD, Wang TH.

Pharmacotherapy. 2003 Jun;23(6):711-9.

PMID:
12820812
6.

Polymorphism of the N-acetyltransferase 2 gene, red meat intake, and the susceptibility of hepatocellular carcinoma.

Huang YS, Chern HD, Wu JC, Chao Y, Huang YH, Chang FY, Lee SD.

Am J Gastroenterol. 2003 Jun;98(6):1417-22.

PMID:
12818290
7.

Cytochrome P450 2E1 genotype and the susceptibility to antituberculosis drug-induced hepatitis.

Huang YS, Chern HD, Su WJ, Wu JC, Chang SC, Chiang CH, Chang FY, Lee SD.

Hepatology. 2003 Apr;37(4):924-30.

PMID:
12668988
8.

Genetic polymorphism of the CYP2E1 gene and susceptibility to Parkinson's disease in Taiwanese.

Wu RM, Cheng CW, Chen KH, Shan DE, Kuo JW, Ho YF, Chern HD.

J Neural Transm (Vienna). 2002 Nov;109(11):1403-14.

PMID:
12454736
9.

Polymorphism of the N-acetyltransferase 2 gene as a susceptibility risk factor for antituberculosis drug-induced hepatitis.

Huang YS, Chern HD, Su WJ, Wu JC, Lai SL, Yang SY, Chang FY, Lee SD.

Hepatology. 2002 Apr;35(4):883-9.

PMID:
11915035
10.

The COMT L allele modifies the association between MAOB polymorphism and PD in Taiwanese.

Wu RM, Cheng CW, Chen KH, Lu SL, Shan DE, Ho YF, Chern HD.

Neurology. 2001 Feb 13;56(3):375-82.

PMID:
11171904
11.

Diagnosis of bladder cancer using telomerase activity in voided urine.

Cheng CW, Chueh SC, Chern HD.

J Formos Med Assoc. 2000 Dec;99(12):920-5.

PMID:
11155745
12.

Characterization of an allelic variant in the nifedipine-specific element of CYP3A4: ethnic distribution and implications for prostate cancer risk. Mutations in brief no. 191. Online.

Walker AH, Jaffe JM, Gunasegaram S, Cummings SA, Huang CS, Chern HD, Olopade OI, Weber BL, Rebbeck TR.

Hum Mutat. 1998;12(4):289.

PMID:
10660343
13.
14.

Genetic polymorphisms of N-acetyltransferase 1 and 2 and risk of cigarette smoking-related bladder cancer.

Hsieh FI, Pu YS, Chern HD, Hsu LI, Chiou HY, Chen CJ.

Br J Cancer. 1999 Oct;81(3):537-41.

15.
16.

Cytochrome P450 1A1 genetic polymorphisms and risk of hepatocellular carcinoma among chronic hepatitis B carriers.

Yu MW, Chiu YH, Yang SY, Santella RM, Chern HD, Liaw YF, Chen CJ.

Br J Cancer. 1999 May;80(3-4):598-603.

18.

Plasma carotenoids, glutathione S-transferase M1 and T1 genetic polymorphisms, and risk of hepatocellular carcinoma: independent and interactive effects.

Yu MW, Chiu YH, Chiang YC, Chen CH, Lee TH, Santella RM, Chern HD, Liaw YF, Chen CJ.

Am J Epidemiol. 1999 Apr 1;149(7):621-9.

PMID:
10192309
19.

Genetic polymorphisms of CYP2E1, GSTM1, and GSTT1; environmental factors and risk of oral cancer.

Hung HC, Chuang J, Chien YC, Chern HD, Chiang CP, Kuo YS, Hildesheim A, Chen CJ.

Cancer Epidemiol Biomarkers Prev. 1997 Nov;6(11):901-5.

20.

Environmental procarcinogen hypothesis of bladder cancer in humans: Dapsone hydroxylation as a susceptibility risk factor for aggressive bladder cancer.

Persad R, Fleming C, Chern HD, Lesnick T, Collins C, Smith P, Schwartz AG, Adedoyin A, Romkes M, Wilkinson GR, Branch RA.

Urol Oncol. 1997 Jan-Feb;3(1):18-26.

PMID:
21227048
21.

Clonal analysis of human recurrent superficial bladder cancer by immunohistochemistry of P53 and retinoblastoma proteins.

Chern HD, Becich MJ, Persad RA, Romkes M, Smith P, Collins C, Li YH, Branch RA.

J Urol. 1996 Nov;156(5):1846-9.

PMID:
8863629
22.

Sandimmun Neoral: Taiwanese experience in renal transplant patients with special reference to patients with existing liver disease.

Lee PH, Hu RH, Tsai KS, Chern HD, Gau YS, Chen RR.

Transplant Proc. 1996 Jun;28(3):1327. No abstract available.

PMID:
8658679
23.

Association of low CYP3A activity with p53 mutation and CYP2D6 activity with Rb mutation in human bladder cancer.

Romkes M, Chern HD, Lesnick TG, Becich MJ, Persad R, Smith P, Branch RA.

Carcinogenesis. 1996 May;17(5):1057-62.

PMID:
8640913
24.

The procarcinogen hypothesis for bladder cancer: activities of individual drug metabolizing enzymes as risk factors.

Branch RA, Chern HD, Adedoyin A, Romkes-Sparks M, Lesnick TG, Persad R, Wilkinson GR, Fleming CM, Dickinson AJ, Sibley G, et al.

Pharmacogenetics. 1995;5 Spec No:S97-102. Review.

PMID:
7581498
25.

Correlation of polymorphic expression of CYP2D6 mRNA in bladder mucosa and tumor tissue to in vivo debrisoquine hydroxylase activity.

Romkes-Sparks M, Mnuskin A, Chern HD, Persad R, Fleming C, Sibley GN, Smith P, Wilkinson GR, Branch RA.

Carcinogenesis. 1994 Sep;15(9):1955-61.

PMID:
7923590
26.

Cytokines and lipopolysaccharide induce nitric oxide synthase in cultured rat pulmonary artery smooth muscle.

Nakayama DK, Geller DA, Lowenstein CJ, Chern HD, Davies P, Pitt BR, Simmons RL, Billiar TR.

Am J Respir Cell Mol Biol. 1992 Nov;7(5):471-6. Erratum in: Am J Respir Cell Mol Biol 1993 Aug;9(2):following 229.

PMID:
1384580

Supplemental Content

Loading ...
Support Center